HUMA
Humacyte·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 0
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About HUMA
Humacyte, Inc.
A clinical-stage biotech platform company that develops universally implantable bioengineered human tissues, complex tissue systems, and organs
Biological Technology
07/01/2020
12/01/2020
NASDAQ Stock Exchange
218
12-31
Common stock
2525 East North Carolina Highway 54, Durham, North Carolina 27713
--
Humacyte, Inc., was incorporated in Delaware on July 1, 2020. The company is pioneering the development and manufacture of off-the-shelf, universally implantable, bioengineered human tissue, advanced tissue structures and organ systems with the goal of improving the lives of patients and transforming medical practice. The company is utilizing a novel, scalable technology platform to develop proprietary bioengineered cell-free human tissue for the treatment of diseases and conditions at a range of anatomical locations across multiple therapeutic areas.
Earnings Call
Q1/2025
Estimate EPS-0.21
Actual EPS0.28
Estimate Revenue764.83K
Actual Revenue517.00K
Humacyte's Q1 2025 Earnings Call: Key Contradictions in Symvess Adoption, Sales Strategy, and FDA Timelines
May 20,2025 11:28
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.18
Actual EPS-0.24
Estimate Revenue1.00M
Actual Revenue301.00K
Humacyte's 2025 Q2 Earnings Call: Unpacking Key Contradictions on Sales, CMS Impact, and FDA Interactions
Aug 11,2025 10:13
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
HUMA has released its 2025 Q3 earnings. EPS was reported at -0.11, versus the expected -0.15, beating expectations. The chart below visualizes how HUMA has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
HUMA has released its 2025 Q3 earnings report, with revenue of 753.00K, reflecting a YoY change of NaN%, and net profit of -17.51M, showing a YoY change of 55.33%. The Sankey diagram below clearly presents HUMA's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
